The company’s consolidated profit excluding minority interest dropped to EGP 105.826 million in January-September from EGP 46.728 million a year earlier ...
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...
GlaxoSmithKline is investing in artificial ... clients in one quarter of the time normally needed. Exscientia and GSK aim to discover novel and selective small molecules for up to 10 disease ...
GlaxoSmithKline has thrown its financial and ... from fungi and screening them for activity against disease targets. GSK has participated in an impressive $175 million Seres C financing for ...
GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...
GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...
GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback